Angiotensin antagonists and fish oil for treating IgA nephropathy

Contributions to Nephrology

Volumn 157, Issue , 2007, Pages 27-36

  Coppo, Rosanna ^a   Amore, A ^a   Peruzzi, L ^a   Mancuso, D ^a   Camilla, R ^a  

^a REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FISH OIL;

CONFERENCE PAPER; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; RENOVASCULAR HYPERTENSION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FISH OILS; GLOMERULONEPHRITIS, IGA; HUMANS; HYPERTENSION, RENAL;

EID: 34249104216     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/0000102285     Document Type: Conference Paper

References (23)

1. Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005;67:799-812.
2. Ashizawa M, Miyazaki M, Abe K, Furusu A, Isomoto H, Harada T, Ozono Y, Sakai H, Koji T, Kohno S: Detection of nuclear factor-kappa B in IgA nephropathy using Southwestern histochemistry. Am J Kidney Dis 2003;42:76-86.
3. Coppo R, Amore A: Aberrant glycosylation in IgA nephropathy (IgAN). Kidney Int 2004;65:1544-1547.
4. Coppo R, Amore A, Gianoglio B, Cacace G, Picciotto G, Roccatello D, Peruzzi L, Piccoli G, De Filippi PG: Angiotensin II local hyperreactivity in the progression of IgA nephropathy. Am J Kidney Dis 1993;21:593-602.
5. Coppo R, D'Amico G: Factors predicting progression of IgA nephropathies. J Nephrol 2005;18:503-512.
6. Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP: Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997;8:199-207.
7. Usui J, Yamagata K, Kai H, Outeki T, Yamamoto S, Muro K, Hirayama A, Yoh K, Tomida C, Hirayama K, Suzuki S, Kobayashi M, Nagata M, Koyama A: Heterogeneity of prognosis in adult IgA nephropathy, especially with mild proteinuria or mild histological features. Intern Med 2001;40:697-702.
8. Cattran DC, Greenwood C, Ritchie S: Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 1994;23:247-254.
9. Kanno Y, Okada H, Saruta T, Suzuki H: Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up. Clin Nephrol 2000;54:360-365.
10. Ruggenenti P, Gherardi G, Benini R, Remuzzi G: Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000;35:1155-1165.
11. Dillon JJ: Treating IgA nephropathy. J Am Soc Nephrol 2001;12:846-847.
12. Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E: Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003;14:1578-1583.
13. Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, Kirschstein M, Linnè T: First prospective double-blind randomized placebo-controlled multicenter trial of ACE-inhibitors (ACE-I) in moderately proteinuric IgA nephropathy in the young (in press).
14. Pozzi C, Del Vecchio L, Casartelli D, Pozzoni P, Andrulli S, Amore A, Peruzzi L, Coppo R, Locatelli F; Adulto e Bambino Study Group; Immunopatologia Renale Study Group of the Italian Society of Nephrology: ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study. J Nephrol 2006;19:508-514.
15. Ma LJ, Nakamura S, Aldigier JC, Rossini M, Yang H, Liang X, Nakamura I, Marcantoni C, Fogo AB: Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 2005;16:966-976.
16. Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M, Minutolo R: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999;33:851-856.
17. Nakao N, Seno H, Kasuga H, Toriyama T, Kawahara H, Fukagawa M: Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABP substudy. Am J Nephrol 2004;24:543-548.
18. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:2026-2033.
19. Suissa S, Hutchinson T, Brophy JM, Kezouh A: ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 2006;69:913-919.
20. Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB: Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 2005;16:3306-3314.
21. Donadio JV Jr, Bergstralh EJ, Offord KP, Spencer DC, Holley KE: A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med 1994;331:1194-1199.
22. Dillon JJ: Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J Am Soc Nephrol 1997;8:1739-1744.
23. Nagy J, Kovacs T, Wittmann I: Renal protection in IgA nephropathy requires strict blood pressure control. Nephrol Dial Transplant 2005;20:1533-1539.